Machine learning and multi-omics technologies for precision cardiovascular medicine: advancing diagnosis, risk
Yaqi Dai1, Liufang Wu1, Hanliangqi Xue1
1The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Insights
Precision medicine, integrating multi-omics and machine learning, enhances cardiovascular disease diagnosis, risk prediction, and treatment selection. These advanced tools offer personalized strategies for better patient outcomes and disease management.
Area of Science:
- Cardiovascular Medicine
- Bioinformatics
- Computational Biology
Background:
- Cardiovascular disease (CVD) presents a significant global health challenge due to its complex nature and patient variability.
- Traditional treatments often lack efficacy for many individuals, highlighting the need for personalized approaches.
- Precision medicine aims to tailor treatments based on individual patient characteristics.
Purpose of the Study:
- To review the application of multi-omics and machine learning in precision cardiovascular medicine.
- To focus on advancements in diagnosis, risk prediction, and treatment response prediction for CVD.
- To explore the potential of these integrated approaches for improving patient management.
Main Methods:
- Systematic review of recent advances in machine learning and multi-omics for precision cardiovascular medicine.
- Analysis of applications in diagnosis, risk prediction, and treatment response prediction.
- Discussion of challenges and opportunities for clinical translation.
Main Results:
- Machine learning and multi-omics improve CVD diagnosis through noninvasive, objective, rapid, and precise evaluation.
- These technologies enable comprehensive risk prediction across the disease spectrum, from prevention to high-risk population screening.
- Individualized prediction of treatment benefits and risks supports informed therapeutic decisions.
Conclusions:
- The integration of multi-omics and machine learning offers new pathways for precise cardiovascular disease management.
- Key challenges for clinical translation include data quality, model validation, transparency, and policy support.
- Continued research and development are crucial for realizing the full potential of precision cardiovascular medicine.
Abstract:
Cardiovascular disease remains a major global health burden. Owing to its complex pathogenesis and marked clinical heterogeneity, conventional one-size-fits-all strategies often yield limited benefit for a substantial proportion of patients. Precision medicine advocates individualized management based on patients' clinical and molecular characteristics to improve outcomes. In this context, multi-omics and machine learning provide critical technical support for precision medicine: multi-omics can capture the full spectrum of cardiovascular disease from molecular alterations to phenotypic manifestations, while machine learning is well-suited to modeling complex associations between high-dimensional, nonlinear omics data and clinical outcomes. Their integration has therefore opened new avenues for the precise management of cardiovascular disease. This review systematically summarizes recent advances in applying machine learning and multi-omics to precision cardiovascular medicine, with a focus on three core domains: diagnosis, risk prediction, and treatment response prediction. In diagnosis, these approaches can assist with definitive diagnosis, early detection, differential diagnosis, and severity assessment, thereby enabling more noninvasive, objective, rapid, and precise evaluation of cardiovascular disease. In risk prediction, they support a comprehensive framework spanning primary prevention, secondary prevention, short-term risk stratification, and screening of high-risk populations, allowing risk management across the full disease course and across diverse patient groups. In addition, they enable individualized prediction of the benefits and risks of pharmacological and surgical treatments, thereby informing therapeutic decision-making. To facilitate clinical translation, several challenges remain particularly important, including data quality control, continuous model validation, improved transparency, clarification of responsibility and accountability, and supportive policies regarding implementation and cost coverage.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease I: Introduction
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
